Crossmark

Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting

Crossref DOI link: https://doi.org/10.1186/s12916-018-1134-3

Published Online: 2018-09-10

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bruijning-Verhagen, P. https://orcid.org/0000-0003-4105-9669
van Dongen, J. A. P.

Verberk, J. D. M.

Pijnacker, R.

van Gaalen, R. D.

Klinkenberg, D.

de Melker, H. E.

Mangen, M.-J. J.
License Information

Text and Data Mining valid from 2018-09-10
More Information

Article History

Received: 23 November 2017

Accepted: 24 July 2018

First Online: 10 September 2018

Ethics approval and consent to participate

: Not applicable

: Not applicable

: PB-V has received a research grant from GlaxoSmithKline for an investigator-initiated study on rotavirus vaccination in medical risk infants. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.